KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Restructuring Costs (2024 - 2025)

Historic Restructuring Costs for Xenon Pharmaceuticals (XENE) over the last 2 years, with Q3 2025 value amounting to $6.7 million.

  • Xenon Pharmaceuticals' Restructuring Costs rose 4735.57% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year change of. This contributed to the annual value of $20.7 million for FY2024, which is 4369.09% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Restructuring Costs is $6.7 million, which was up 4735.57% from $6.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Restructuring Costs' 5-year high stood at $6.7 million during Q3 2025, with a 5-year trough of $4.6 million in Q3 2024.